Prevalence of Antibody against Angiotensin II Type 1 Receptor (AT1R) Among Thai Kidney Transplant Patients

Viboon, S.; Townamchai, Natavudh; Phiancharoen, S.; Kupatawintu, Pawinee; Dhitivat, V; Nathalang, Oytip

doi:10.1016/j.transproceed.2018.03.020

Cited by 6 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15 Previous studies have reported 9.4%-48.5% anti-AT1R positivity rates when the threshold was set at 17 U/mL. [16][17][18][19][20][21][22][23][24][25][26] In this study, 7.1% of patients had anti-AT1R antibody pre-KT, with a cutoff value of 17 U/mL.…”

Section: Discussionmentioning

confidence: 56%

“…The prevalence of AT1R‐Ab pre‐ and post‐KT varied from 2.1% to 59% and 3.8% to 51.5% owing to the differences between analyzed populations, positivity threshold used for AT1R‐Ab detection (2–30 U/mL), time of assessment related to the time of KT, donor type, and type of induction treatment 15 . Previous studies have reported 9.4%–48.5% anti‐AT1R positivity rates when the threshold was set at 17 U/mL 16–26 . In this study, 7.1% of patients had anti‐AT1R antibody pre‐KT, with a cutoff value of 17 U/mL.…”

Section: Discussionmentioning

confidence: 79%

See 1 more Smart Citation

Association between anti‐endothelial antigen antibodies and allograft rejection in kidney transplantation

Lee,

Shin,

Kim

et al. 2023

Clinical Laboratory Analysis

View full text Add to dashboard Cite

BackgroundEndothelial cells are vital in the transplant immune system as semiprofessional antigen‐presenting cells. Few studies have investigated the importance of anti‐endothelin subtype A receptor (ETAR) antibodies in kidney transplantation. Here, we aimed to analyze the association between anti‐angiotensin II type I receptor (AT1R) and anti‐ETAR antibodies and the association between the presence of anti‐endothelial antibodies and the risk of allograft rejection in kidney transplantation.MethodsIn total, 252 patients who underwent kidney transplantation were enrolled in this study. Antibodies for human leukocyte antigens (HLAs) and non‐HLAs were analyzed immediately before transplantation. Patients were categorized based on the occurrence of antibody‐mediated rejection (AMR) or T‐cell‐mediated rejection (TCMR) by 2017 Banff classification. All p‐values were two‐tailed, and statistical significance was set at p < 0.05.ResultsPatients with anti‐AT1R antibodies had a 3.49‐fold higher risk of TCMR than those without anti‐AT1R antibodies. Patients with anti‐ETAR antibodies had a 5.84‐fold higher risk of AMR than those without anti‐ETAR antibodies. The hazard ratio of AMR in patients with both HLA DSAs and anti‐ETAR antibodies, relative to patients without anti‐ETAR antibodies and HLA DSAs, was 32.85 (95% CI = 1.82–592.91).ConclusionOur findings indicated that anti‐ETAR antibodies are associated with AMR, and patients with both anti‐ETAR antibodies and de novo HLA DSAs were at a high risk of AMR.

show abstract